A new study shows that a microbicide gel is highly effective in block infection by the AIDS virus in a non-human primate model. This is a gel, which can be topically applied and could represent a powerful preventative agent against sexual transmission of HIV.
In the paper published December 6 in the Open Access journal PLOS Pathogens, Dereuddre-Bosquet and colleagues from the European Combined Highly Active Anti-Retroviral Microbicides (CHAARM) Consortium describe the gel’s key ingredient, which are small peptides engineered to present a decoy to bind up the virus and prevent it from entering and infecting the cells of the body.
Worldwide, the scientific community is working on the development of a vaccine against HIV. Meanwhile, research is also focused on the reduction of the spread of the virus by the application of a microbicide, gel to protect users during intercourse, which is a time of first exposure to virus. To date, few treatments that block virus entry have shown promising protection.
Dereuddre-Bosquet et al. engineered peptides named “miniCD4s” because they mimic the CD4 receptor used by HIV to gain entry into immune cells of the body. The study shows that the miniCD4s blocks HIV entry into isolated cells in a dish and tissue models that mimic mucous membranes, which are points of virus entry. The authors then formulated miniCD4s at 0.3% in a microbicide gel that was vaginally applied to six female cynomolgus macaques monkeys for one hour, before the animals were given a high dose of the virus also in the vagina. This dose, though ordinarily made the animals highly infectious, five of the six were completely protected from HIV infection. They were also unable to detect any antibodies to the virus in the plasma of the animals, indicating that the virus was completely repelled and there was full protection. No trace of virus was found in any body tissue
This study provides a proof of principle for a promising strategy, for the prevention and protection against HIV transmission during sexual intercourse. Importantly, the protection was demonstrated in a non human primate model which represents an essential step prior needed to progress to a prospective clinical trial.